2.04 USD
0 (0%)
Last: Feb 3, 2026, 08:00 PM
TRAW gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While TRAW seems to be doing ok healthwise, there are quite some concerns on its profitability. TRAW has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- TRAW had positive earnings in the past year.
- In the past year TRAW has reported a negative cash flow from operations.
- In the past 5 years TRAW always reported negative net income.
- TRAW had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- TRAW's Return On Assets of 777.75% is amongst the best of the industry. TRAW outperforms 100.00% of its industry peers.
- With an excellent Return On Equity value of 2051.21%, TRAW belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 777.75% | ||
| ROE | 2051.21% | ||
| ROIC | N/A |
ROA(3y)-116.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TRAW's Profit Margin of 3279.34% is amongst the best of the industry. TRAW outperforms 100.00% of its industry peers.
- TRAW does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3279.34% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
- TRAW has more shares outstanding than it did 1 year ago.
- There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- TRAW has an Altman-Z score of -76.54. This is a bad value and indicates that TRAW is not financially healthy and even has some risk of bankruptcy.
- TRAW has a worse Altman-Z score (-76.54) than 94.24% of its industry peers.
- There is no outstanding debt for TRAW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -76.54 |
ROIC/WACCN/A
WACC9.54%
2.3 Liquidity
- TRAW has a Current Ratio of 1.22. This is a normal value and indicates that TRAW is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.22, TRAW is doing worse than 80.10% of the companies in the same industry.
- TRAW has a Quick Ratio of 1.22. This is a normal value and indicates that TRAW is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of TRAW (1.22) is worse than 72.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.22 | ||
| Quick Ratio | 1.22 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 119.99% over the past year.
- TRAW shows a strong growth in Revenue. In the last year, the Revenue has grown by 1159.29%.
EPS 1Y (TTM)119.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
Revenue 1Y (TTM)1159.29%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- Based on estimates for the next years, TRAW will show a very strong growth in Earnings Per Share. The EPS will grow by 25.82% on average per year.
- TRAW is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 384.76% yearly.
EPS Next Y99.97%
EPS Next 2Y40.89%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue Next Year1117.39%
Revenue Next 2Y-41.42%
Revenue Next 3Y384.76%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 0.07 indicates a rather cheap valuation of TRAW.
- TRAW's Price/Earnings ratio is rather cheap when compared to the industry. TRAW is cheaper than 99.48% of the companies in the same industry.
- When comparing the Price/Earnings ratio of TRAW to the average of the S&P500 Index (28.18), we can say TRAW is valued rather cheaply.
- TRAW is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.07 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TRAW's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as TRAW's earnings are expected to grow with 25.82% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y40.89%
EPS Next 3Y25.82%
5. Dividend
5.1 Amount
- No dividends for TRAW!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TRAW (2/3/2026, 8:00:02 PM)
2.04
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13
Earnings (Next)03-30 2026-03-30/amc
Inst Owners16.14%
Inst Owner Change0.59%
Ins Owners6.95%
Ins Owner Change4.88%
Market Cap16.30M
Revenue(TTM)2.85M
Net Income(TTM)93.33M
Analysts82.86
Price Target8.16 (300%)
Short Float %8.39%
Short Ratio1.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2132.84%
Min Revenue beat(2)-100%
Max Revenue beat(2)4365.69%
Revenue beat(4)1
Avg Revenue beat(4)1064.22%
Min Revenue beat(4)-100%
Max Revenue beat(4)4365.69%
Revenue beat(8)1
Avg Revenue beat(8)527.74%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)80.02%
EPS NY rev (1m)0%
EPS NY rev (3m)99.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1117.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.07 | ||
| Fwd PE | N/A | ||
| P/S | 5.73 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.98 | ||
| P/tB | 10.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)28.26
EY1385.29%
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-2.38
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0.36
BVpS0.51
TBVpS0.19
PEG (NY)0
PEG (5Y)N/A
Graham Number18.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 777.75% | ||
| ROE | 2051.21% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 3279.34% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-116.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.22 | ||
| Quick Ratio | 1.22 | ||
| Altman-Z | -76.54 |
F-Score6
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
EPS Next Y99.97%
EPS Next 2Y40.89%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue 1Y (TTM)1159.29%
Revenue growth 3Y0%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year1117.39%
Revenue Next 2Y-41.42%
Revenue Next 3Y384.76%
Revenue Next 5YN/A
EBIT growth 1Y34.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-66.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.67%
OCF growth 3YN/A
OCF growth 5YN/A
TRAWS PHARMA INC / TRAW FAQ
What is the fundamental rating for TRAW stock?
ChartMill assigns a fundamental rating of 4 / 10 to TRAW.
What is the valuation status for TRAW stock?
ChartMill assigns a valuation rating of 4 / 10 to TRAWS PHARMA INC (TRAW). This can be considered as Fairly Valued.
How profitable is TRAWS PHARMA INC (TRAW) stock?
TRAWS PHARMA INC (TRAW) has a profitability rating of 3 / 10.
What is the valuation of TRAWS PHARMA INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TRAWS PHARMA INC (TRAW) is 0.07 and the Price/Book (PB) ratio is 3.98.
What is the expected EPS growth for TRAWS PHARMA INC (TRAW) stock?
The Earnings per Share (EPS) of TRAWS PHARMA INC (TRAW) is expected to grow by 99.97% in the next year.